ATRS Antares Pharma Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * GRAHAM PETER J	2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [ ATRS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) EVP General Counsel, Secretary
(Last)          (First)          (Middle) C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300	3. Date of Earliest Transaction (MM/DD/YYYY) 6/10/2021
(Street) EWING, NJ 08628 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	6/10/2021		A		85973 (1)	A	$4.42	632231	D
Common Stock	6/11/2021		F(2)		23010 (2)	D(2)	$4.45	609221	D
Common Stock	6/13/2021		F(2)		14790 (2)	D(2)	$4.45	594431	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.42	6/10/2021		A		163963 (3)		(4)	6/10/2031	Common Stock	163963	$0.00	163963	D

Explanation of Responses:
(1)	Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
(2)	Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold.
(3)	Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.
(4)	The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
GRAHAM PETER J C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING, NJ 08628			EVP General Counsel, Secretary

Signatures
/s/Lisa M. Kallebo as attorney-in-fact for Peter J. Graham		6/14/2021
**Signature of Reporting Person		Date